Blog

27 Mar

Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

March 26, 2023
Posted by Jitendra

PALO ALTO, CALIFORNIA – March 27, 2023 (GLOBE NEWSWIRE) - Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced today that there are more...

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Prospectus [Rule 424(b)(3)]

March 21, 2023
Posted by Ulisses

21 Mar

SEC FIlings

Current report

March 21, 2023
Posted by Ulisses

21 Mar

Press Release

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

March 21, 2023
Posted by Jitendra

Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain management products (ZTlido®, Gloperba® and ElyxybTM) for the treatment of...

20 Mar

SEC FIlings